High C-Terminal Fibroblast Growth Factor-23, Intact Parathyroid Hormone, and Interleukin-6 as Determinants of Valvular Calcification in Regular Hemodialysis Patients

被引:4
作者
Kandarini, Yenny [1 ]
Mahadita, Gede Wira [1 ]
Herawati, Sianny [2 ]
Wibhuti, Ida Bagus Rangga [3 ]
Widiana, I. Gde Raka [1 ]
Ayu, Nyoman Paramita [1 ]
机构
[1] Udayana Univ, Dept Internal Med, Div Nephrol & Hypertens, Sanglah Hosp, PB Sudirman St, Denpasar 80234, Bali, Indonesia
[2] Udayana Univ, Dept Clin Pathol & Lab Med, Sanglah Hosp, Denpasar, Bali, Indonesia
[3] Udayana Univ, Dept Cardiol & Vasc Med, Sanglah Hosp, Denpasar, Bali, Indonesia
来源
INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2022年 / 15卷
关键词
dialysis; end-stage renal disease; inflammation; hormone; STAGE RENAL-DISEASE; VALVE CALCIFICATION; VASCULAR CALCIFICATION; RISK-FACTORS; MORTALITY; INFLAMMATION;
D O I
10.2147/IJGM.S359168
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Biggest cause of death in chronic kidney disease-hemodialysis (CKD-HD) patients is cardiovascular disease (CVD). Cardiovascular disease is often associated with mineral bone disorders (MBD), especially vascular and valvular calcification. Biomarkers such as C-terminal-fibroblast growth factor-23 (FGF-23), intact parathyroid hormone (iPTH), and interleukin-6 (IL-6) were investigated. Only few studies have focused on valvular calcification in CKD-HD patients, with controversial results. The present study aimed to investigate whether high C-terminal-FGF-23, iPTH, and IL-6 can be used as determinants of valvular calcification in CKD-MBD patients undergoing regular HD. Patients and Methods: This was an analytical cross-sectional study which involved CKD-HD patients aged 18-60 years with no history of CVD, malignancy, and diabetes mellitus. C-terminal FGF-23 was measured using enzyme-linked immunosorbent assay (ELISA) kit, iPTH using chemiluminescent immunometric method, and IL-6 using sandwich enzyme immunoassay technique. Valvular calcification on aortic and mitral valves was examined with echocardiography. Data analysis was done using Chi-square d test or Fisher's exact test as appropriate and multivariate logistic regression analysis. Results: Bivariate analysis with Fisher's exact test showed significant association of prevalence ratio (PR) of C-terminal FGF-23 (PR = 1.33; p = 0.003; CI (1.017-1.748)), iPTH (PR = 1.361; p = 0.002; CI (1.02-1.816)), and IL-6 (PR = 1.2; p = 0.019; CI (1.000-1.446)) with valvular calcification. Multivariate analysis with logistic regression showed high C-terminal FGF-23 (exp (B) value of 16.44; p = 0.045; CI (1.07-252.75)), iPTH (exp (B) value of 33.312; p = 0.016; CI (1.94-571.71)), and IL-6 (exp (B) value of 21.58; p = 0.0381; CI (1.18-394.87)) were determinants of valvular calcification in CKD-MBD patients undergoing regular HD. Conclusion: This study demonstrated that high C-terminal FGF-23, iPTH, and IL-6 were determinants of valvular calcification in CKD-MBD patients undergoing regular HD.
引用
收藏
页码:4227 / 4236
页数:10
相关论文
共 50 条
  • [41] Low Magnesium Levels and FGF-23 Dysregulation Predict Mitral Valve Calcification as well as Intima Media Thickness in Predialysis Diabetic Patients
    Silva, Ana Paula
    Gundlach, Kristina
    Buechel, Janine
    Jeronimo, Teresa
    Fragoso, Andre
    Silva, Claudia
    Guilherme, Patricia
    Santos, Nelio
    Faisca, Marlia
    Neves, Pedro
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2015, 2015
  • [42] Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements
    Smith, Edward R.
    Cai, Michael M.
    McMahon, Lawrence P.
    Holt, Stephen G.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) : 3357 - 3365
  • [43] Soleymanian T, 2016, NEPHROUROL MON, V9, P41
  • [44] Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
    Su, Hua
    Lei, Chun-Tao
    Zhang, Chun
    [J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [45] Renal and extrarenal effects of fibroblast growth factor 23
    Vervloet, Marc
    [J]. NATURE REVIEWS NEPHROLOGY, 2019, 15 (02) : 109 - 120
  • [46] Prevention and treatment of hyperphosphatemia in chronic kidney disease
    Vervloet, Marc G.
    van Ballegooijen, Adriana J.
    [J]. KIDNEY INTERNATIONAL, 2018, 93 (05) : 1060 - 1072
  • [47] Inflammation and the bone-vascular axis in end-stage renal disease
    Viaene, L.
    Behets, G. J.
    Heye, S.
    Claes, K.
    Monbaliu, D.
    Pirenne, J.
    D'Haese, P. C.
    Evenepoel, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2016, 27 (02) : 489 - 497
  • [48] Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease
    Wang, AYM
    Ho, SSY
    Wang, M
    Liu, EKH
    Ho, S
    Li, PKT
    Lui, SF
    Sanderson, JE
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (03) : 327 - 332
  • [49] Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis
    Wang, Zhe
    Jiang, Aili
    Wei, Fang
    Chen, Haiyan
    [J]. BMC CARDIOVASCULAR DISORDERS, 2018, 18
  • [50] Zaki SA., 2018, J. Egypt. Soc. Nephrol. Transplant, V18, P17, DOI [10.4103/jesnt.jesnt_28_17, DOI 10.4103/JESNT.JESNT_28_17]